Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by FARHAD RAVANDI-KASHANI and SRDAN VERSTOVSEK.
FARHAD RAVANDI-KASHANI
Connection Strength
2.321
SRDAN VERSTOVSEK
  1. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar; 168(5):646-53.
    View in: PubMed
    Score: 0.129
  2. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar; 15(3):171-6.
    View in: PubMed
    Score: 0.129
  3. The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia. Clin Cancer Res. 2013 Jan 15; 19(2):327-35.
    View in: PubMed
    Score: 0.114
  4. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17; 119(20):4614-8.
    View in: PubMed
    Score: 0.108
  5. Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity. Leuk Lymphoma. 2012 Sep; 53(9):1839-41.
    View in: PubMed
    Score: 0.108
  6. A potential role of ruxolitinib in leukemia. Expert Opin Investig Drugs. 2011 Aug; 20(8):1159-66.
    View in: PubMed
    Score: 0.102
  7. Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy. Blood. 2010 Dec 23; 116(26):5818-23; quiz 6153.
    View in: PubMed
    Score: 0.098
  8. Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 2009 Dec 15; 115(24):5746-51.
    View in: PubMed
    Score: 0.093
  9. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10; 27(32):5425-30.
    View in: PubMed
    Score: 0.091
  10. Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res. 2009 Jan 01; 15(1):368-73.
    View in: PubMed
    Score: 0.087
  11. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009 Feb 01; 27(4):504-10.
    View in: PubMed
    Score: 0.086
  12. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol. 2006 Dec; 24(4):181-8.
    View in: PubMed
    Score: 0.075
  13. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15; 107(12):4658-62.
    View in: PubMed
    Score: 0.071
  14. T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma. 2005 Nov; 6(3):234-9.
    View in: PubMed
    Score: 0.070
  15. Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.
    View in: PubMed
    Score: 0.047
  16. A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.
    View in: PubMed
    Score: 0.042
  17. The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy. Cancer. 2016 Apr 15; 122(8):1160-8.
    View in: PubMed
    Score: 0.035
  18. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):155-162.e1.
    View in: PubMed
    Score: 0.030
  19. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk. 2014 Apr; 14(2):93-7.
    View in: PubMed
    Score: 0.030
  20. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):223-30.
    View in: PubMed
    Score: 0.030
  21. Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials. Clin Lymphoma Myeloma Leuk. 2013 Dec; 13(6):693-9.
    View in: PubMed
    Score: 0.030
  22. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol. 2013 Dec; 88(12):1024-9.
    View in: PubMed
    Score: 0.030
  23. Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies. Leuk Res. 2013 Nov; 37(11):1461-7.
    View in: PubMed
    Score: 0.030
  24. Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):477-84.
    View in: PubMed
    Score: 0.029
  25. Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities. Blood. 2013 Jun 13; 121(24):4867-74.
    View in: PubMed
    Score: 0.029
  26. Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy. Haematologica. 2012 Jul; 97(7):1029-35.
    View in: PubMed
    Score: 0.027
  27. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood. 2011 Oct 20; 118(16):4353-8.
    View in: PubMed
    Score: 0.026
  28. The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint? Clin Lymphoma Myeloma Leuk. 2011 Oct; 11(5):421-6.
    View in: PubMed
    Score: 0.026
  29. Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy. Haematologica. 2011 Jun; 96(6):918-21.
    View in: PubMed
    Score: 0.025
  30. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):54-9.
    View in: PubMed
    Score: 0.025
  31. A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer. 2011 Mar 15; 117(6):1236-44.
    View in: PubMed
    Score: 0.025
  32. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica. 2011 Jan; 96(1):62-8.
    View in: PubMed
    Score: 0.024
  33. Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulating factor. Cancer. 2011 Feb 01; 117(3):572-80.
    View in: PubMed
    Score: 0.024
  34. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3880-9.
    View in: PubMed
    Score: 0.024
  35. Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer. 2010 Jan 01; 116(1):93-7.
    View in: PubMed
    Score: 0.023
  36. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009 Oct 01; 27(28):4760-6.
    View in: PubMed
    Score: 0.023
  37. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood. 2009 May 21; 113(21):5058-63.
    View in: PubMed
    Score: 0.022
  38. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008 Oct 15; 113(8):2090-6.
    View in: PubMed
    Score: 0.021
  39. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2008 Sep 01; 112(5):1638-45.
    View in: PubMed
    Score: 0.021
  40. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
    View in: PubMed
    Score: 0.021
  41. A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. Leukemia. 2008 May; 22(5):965-70.
    View in: PubMed
    Score: 0.021
  42. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer. 2008 Feb 15; 112(4):837-45.
    View in: PubMed
    Score: 0.020
  43. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007 Apr 15; 109(8):1556-60.
    View in: PubMed
    Score: 0.019
  44. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007 Feb; 136(4):624-7.
    View in: PubMed
    Score: 0.019
  45. Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer. 2006 Oct 01; 107(7):1525-9.
    View in: PubMed
    Score: 0.019
  46. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2006 Sep 01; 12(17):5165-73.
    View in: PubMed
    Score: 0.018
  47. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006 Nov 15; 108(10):3271-9.
    View in: PubMed
    Score: 0.018
  48. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse. Br J Haematol. 2006 Jul; 134(1):58-60.
    View in: PubMed
    Score: 0.018
  49. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15; 106(12):2645-51.
    View in: PubMed
    Score: 0.018
  50. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood. 2006 Jul 01; 108(1):45-51.
    View in: PubMed
    Score: 0.018
  51. The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res. 2006 Jul; 30(7):801-11.
    View in: PubMed
    Score: 0.017
  52. Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res. 2005 Nov 01; 11(21):7817-24.
    View in: PubMed
    Score: 0.017
  53. Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood. 2006 Feb 01; 107(3):880-4.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.